A Wearable Remote Data Capture Solution for Home-Based Gait Assessment in Multiple Sclerosis.
The goal of this study is to validate an MS Gait Remote Capture and Analysis (MS-GRCA) system based on wearable shoe-based motion sensors for home-based and repeatable gait assessments.Participants (n=30) will complete a three-step validation study consisting of 4 study visits: one baseline in-clinic gait assessment including clinical standard, and MS-GRCA gait evaluation; three remote supervised self-administered gait assessments with the MS-GRCA. The three remote assessment will be performed via Webex or Zoom and monitored in real-time by a study team member.
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The optimal treatment for children and adolescents with Ph+ ALL has not yet been determined. There is now a general consensus among the North American and European Childhood ALL treatment groups that Ph+ ALL patients with a favorable early response to the combination of chemotherapy and tyrosine kinase inhibitor (TKI) treatment can be treated without HSCT in first complete remission (CR1), while those with a suboptimal early response are more appropriately treated with HSCT in CR1. Two different cytotoxic chemotherapy backbones have been used in combination with TKI in recent North American and European pediatric Ph+ ALL trials: 1) the COG regimen (used in COG AALL0031with imatinib and in AALL0622 with dasatinib), and 2) the EsPhALL regimen used in Europe with imatinib (initial EsPhALL trial) and in a joint COG/EsPhALL (AALL1122) trial with dasatinib. Both of these regimens are quite intensive, leading to a high frequency of treatment-related complications, including prolonged myelosuppression and life-threatening infections. On AALL1122, approximately 5% of patients treated with the EsPhALL regimen plus TKI without HSCT died due to toxicity, accounting for a significant percentage of events observed in the non-HSCT population in these trials. The goal of this trial is to reduce treatment-related morbidity and mortality without adversely impacting disease free survival (DFS) in Standard Risk (SR) patients, who comprise approximately 80-85% of all pediatric Ph+ ALL patients. The proposed AALL1631 trial will test whether favorable outcomes may be achieved when imatinib is combined with a less intensive chemotherapy backbone in pediatric Ph+ ALL patients defined as SR based on MRD measurements early in treatment. We plan to randomly compare the two cytotoxic backbones using a non-inferiority design in order to detect whether there is a lack of significant decrement in DFS with the less intensive chemotherapy regimen. The randomized trial design will also allow us to directly compare toxicities associated with the two regimens.
AbbVie M21-446: A single arm open-label study to evaluate the efficacy and safety of ABBV-668 in Subjects with Moderate to Severe Ulcerative Colitis
See protocol
Abdominal Core Health & Hernia Program | NYU Langone Health
NYU Langone’s Abdominal Core Health and Hernia Program provides simple and complex hernia repair and abdominal wall reconstruction.
Abdominal Core Health & Hernia Program Doctors | NYU Langone Health
Find a doctor at the Abdominal Core Health & Hernia Program at NYU Langone.
Ablation for Kidney Cancer | NYU Langone Health
NYU Langone doctors may use extreme cold or heat, called ablation, to destroy kidney cancer tumors.
Ablation Therapies for Liver Cancer & Liver Metastases | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may use heat therapy, called ablation, to manage liver cancer and liver metastases.
Ablation Therapy for Non-Small Cell Lung Cancer | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may recommend ablation therapies for people who have non-small cell lung cancer.
Abnormal Pap Test Results | NYU Langone Health
Doctors at NYU Langone are experts in assessing Pap test results and determining if further testing or treatment is needed.
About Hassenfeld Children’s Hospital | NYU Langone Health
Hassenfeld Children’s Hospital at NYU Langone is home to more than 400 doctors representing more than 35 medical specialties.